EconPapers    
Economics at your fingertips  
 

The addition of neoadjuvant pertuzumab for the treatment of HER2+ breast cancer: a cost estimate with real-world data

Andreia Borges, Filipa Pereira, Patrícia Redondo, Luís Antunes, Cláudia Vieira, Pedro Antunes, Maria José Bento, Susana Sousa, José Machado Lopes, Francisco Rocha-Gonçalves, Joaquim Abreu Sousa, Deolinda Sousa Pereira and Marina Borges ()
Additional contact information
Andreia Borges: Portuguese Oncology Institute of Porto (IPO Porto)
Filipa Pereira: Portuguese Oncology Institute of Porto (IPO Porto)
Patrícia Redondo: Portuguese Oncology Institute of Porto (IPO Porto)
Luís Antunes: Portuguese Oncology Institute of Porto (IPO Porto)
Cláudia Vieira: Portuguese Oncology Institute of Porto (IPO Porto)
Pedro Antunes: Portuguese Oncology Institute of Porto (IPO Porto)
Maria José Bento: Portuguese Oncology Institute of Porto (IPO Porto)
Susana Sousa: Portuguese Oncology Institute of Porto (IPO Porto)
José Machado Lopes: Portuguese Oncology Institute of Porto (IPO Porto)
Francisco Rocha-Gonçalves: Luz Saúde
Joaquim Abreu Sousa: Portuguese Oncology Institute of Porto (IPO Porto)
Deolinda Sousa Pereira: Portuguese Oncology Institute of Porto (IPO Porto)
Marina Borges: Portuguese Oncology Institute of Porto (IPO Porto)

Health Economics Review, 2021, vol. 11, issue 1, 1-13

Abstract: Abstract Background Breast cancer (BC) is largely prevalent worldwide. HER2-positive BC account for roughly 20–25% of all BC cases and has an overall survival lower than other BC. Innovation on BC therapeutics is a constant, but novel therapies have higher costs. Therefore, cost-effectiveness research is essential to provide healthcare decision-makers with solid foundations for a resource allocation. This study aims to estimate the average direct medical costs/patient and cost-effectiveness of adding pertuzumab in neoadjuvant treatment (NeoT) for HER2-positive breast cancer (BC). Methods Two retrospective real-world consecutive cohorts of ≥18yo female patients diagnosed with HER2-positive BC treated with NeoT at the Breast Clinic of IPO-Porto were studied. The AC-DH regimen (2012–2015) comprised 8 cycles of neoadjuvant therapy (4 cycles of doxorubicin + cyclosphosphamide followed by 4 cycles ofdocetaxel + trastuzumab), while the AC-DHP regimen (2015–2017) included also pertuzumab as NeoT. NeoT was followed by surgery and adjuvant trastuzumab. Micro-costing technique and a bottom-up approach was used comprising all medical direct costs from the hospital perspective. Unit costs were obtained from government official prices or from IPO-Porto costing system. Costs were adjusted to 2017 and are expressed in euros. Multivariable logistic regression models were used for effectiveness assessment, while generalized linear models with gamma distribution were used for costs. ICER was calculated using the pathological complete response (pCR) as the preferential measure of effectiveness. Sensitivity analysis was also performed. Results AC-DHP (n = 40) and AC-DH (n = 54) cohorts had heterogenous patient profiles (median age 43y/53y; 67.5%/59.3% positive HR; 60.0%/27.8% operable; 25.0%/24.1% inflammatory, respectively). The AC-DHP average total cost/patient was 56,375€, with pertuzumab accounting for 13,978€ (24.79%) and increasing in 15,982€ the average cost/patient (p

Keywords: Pertuzumab; Neoadjuvant treatment; HER2-positive breast cancer; Cost-effectiveness analysis (search for similar items in EconPapers)
Date: 2021
References: View complete reference list from CitEc
Citations: Track citations by RSS feed

Downloads: (external link)
http://link.springer.com/10.1186/s13561-021-00332-0 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:hecrev:v:11:y:2021:i:1:d:10.1186_s13561-021-00332-0

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/13561

DOI: 10.1186/s13561-021-00332-0

Access Statistics for this article

Health Economics Review is currently edited by J. Matthias Graf von der Schulenburg

More articles in Health Economics Review from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

 
Page updated 2022-05-12
Handle: RePEc:spr:hecrev:v:11:y:2021:i:1:d:10.1186_s13561-021-00332-0